NUAK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2014378	0.54	3/20
SCHEMBL2019205	0.52	3/20
SCHEMBL2042083	0.51	3/20
SCHEMBL2270032	0.51	3/20
SCHEMBL2044932	0.49	3/20
SCHEMBL2267061	0.48	3/20
SCHEMBL2266913	0.47	3/20
SCHEMBL2038214	0.45	3/20
SCHEMBL93699	1.00	2/20
Tofacitinib (SCHEMBL322753)	1.00	2/20
Tofacitinib (SCHEMBL1120705)	1.00	2/20
Tofacitinib (SCHEMBL1374185)	1.00	2/20
SCHEMBL1706773	0.97	2/20
SCHEMBL2323500	0.85	2/20
SCHEMBL3065509	0.85	2/20
SCHEMBL2123577	0.85	2/20
SCHEMBL2320931	0.80	2/20
SCHEMBL1846276	0.78	2/20
SCHEMBL2319641	0.77	2/20
SCHEMBL2148397	0.75	2/20

Clinical trials — most relevant to NUAK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NUAK2 binder may also engage these)

Protein	Name	Similarity
Q5R7G9	—	1.000	Q5R7G9 →
Q66HE5	—	0.999	Q66HE5 →
Q8BZN4	—	0.996	Q8BZN4 →
Q8BWQ5	—	0.994	Q8BWQ5 →
Q641K5	—	0.993	Q641K5 →
NUAK1	NUAK family SNF1-like kinase 1	0.993	landscape →
Q60700	—	0.993	Q60700 →
Q68UT7	—	0.992	Q68UT7 →
Q63553	—	0.992	Q63553 →
Q3ULB5	—	0.991	Q3ULB5 →
Q8VDU5	—	0.991	Q8VDU5 →
Q924U5	—	0.990	Q924U5 →
Q8K330	—	0.990	Q8K330 →
Q6P0Q8	—	0.990	Q6P0Q8 →
Q76I79	—	0.990	Q76I79 →
O88831	—	0.989	O88831 →
D3ZML2	—	0.989	D3ZML2 →
Q5R8Z4	—	0.989	Q5R8Z4 →
MAP3K9	Mitogen-activated protein kinase kinase kinase 9	0.989	landscape →
O70405	—	0.989	O70405 →
DYRK1B	Dual specificity tyrosine-phosphorylation-regulated kinase 1B	0.989	landscape →
Q60670	—	0.988	Q60670 →
SIK1	Serine/threonine-protein kinase SIK1	0.988	landscape →
Q8CIP4	—	0.988	Q8CIP4 →
Q3UIZ8	—	0.988	Q3UIZ8 →
CAMKK2	Calcium/calmodulin-dependent protein kinase kinase 2	0.988	landscape →
MAST3	Microtubule-associated serine/threonine-protein kinase 3	0.988	landscape →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.987	landscape →
Q8C078	—	0.987	Q8C078 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.987	landscape →